A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Luis G Paz-Ares, David Vicente, Ali Tafreshi et al. · Journal of Thoracic Oncology · 2020
Cited by 631 works. doi:10.1016/j.jtho.2020.06.015
Authors
- Luis G Paz-Ares
- David Vicente
- Ali Tafreshi
- Andrew George Robinson
- Hector Josè Soto Parra
- Julien Mazières
- İrfan Çiçin
- Balazs Medgyasszay
- Jerónimo Rafael Rodríguez‐Cid
- Isamu Okamoto
- Sung-Sook Lee
- Rodryg Ramlau
- Vladimir Ivanovich Vladimirov
- Ying Cheng
- Xuan Deng
- Ying Zhang
- Bilal Piperdi
- Balázs Halmos
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- Weekly nab -Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
- IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
- Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics